Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial Active — Not Recruiting NCT03270982

Comprehensive Segmental Revision System

Comprehensive Segmental Revision System — Active Not Recruiting • Oncology • NCT03270982.

📅 09 Jun 2026 ⏱ 1 min read
Active — Not Recruiting
Check the registry for current status and eligibility criteria.
Status
Active — Not Recruiting
NCT ID
NCT03270982
Start
2016-04
Completion
2035-12
ClinicaliQ Trial Snapshot
  • Comprehensive Segmental Revision System — Active Not Recruiting • Oncology • NCT03270982.
  • A study evaluating how well the Comprehensive Segmental Revision System works for complex spinal reconstruction surgery.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

Clinical Data evaluation to document the performance and clinical outcomes of the Comprehensive Segmental Revision System. Conditions: Degenerative Disease, Oncology, Revision Surgery, Trauma, Rheumatoid Arthritis Interventions: Comprehensive SRS Replacement Lead Sponsor: Zimmer Biomet Planned Enrollment: 105 participants

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
‘My cancer spread while I waited months for surgery’: The cost of England’s cancer wait times
Oncology · BBC Health · 10 Sep 2026
England's cancer surgery waiting times have deteriorated despite government initiatives aimed at improving them, with patients experiencing significant delays that may allow…
View brief →
Clinical Brief
Wellbeing support demand for cancer patients grows
Oncology · BBC Health · 25 Oct 2026
Key Takeaways for Clinical Practice Cancer patients are reporting increased demand for wellbeing support services, suggesting current provision may not meet patient…
View brief →
Clinical Brief
Pope does not need further treatment after lung cancer surgery
Oncology · BBC Health · 21 Oct 2026
Localised lung adenocarcinoma identified post-operatively, indicating early-stage disease suitable for surgical intervention alone No adjuvant therapy deemed necessary following successful surgical resection…
View brief →
Guideline
Lisocabtagene maraleucel for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment (terminated evaluation)
Oncology · 20 Aug 2026
This NICE evaluation was terminated, meaning lisocabtagene maraleucel is not currently recommended for routine NHS use in relapsed or refractory follicular lymphoma—do…
View guideline →
Clinical Brief
Pope pictured for first time since surgery and cancer diagnosis
Oncology · BBC Health · 16 Oct 2026
Pope Francis underwent lung cancer surgery at Gemelli Hospital in Rome; public appearance marks recovery milestone following diagnosis First photographic evidence post-operatively…
View brief →
Guideline
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy
Oncology · 07 Oct 2026
Trastuzumab deruxtecan is recommended by NICE as a treatment option for HER2-low metastatic or unresectable breast cancer, making it suitable for patients…
View guideline →